The background of the slide is a dense field of microscopic, red-tinted circular structures, likely cells or bubbles, creating a textured, organic appearance. A dark red horizontal band is positioned across the middle of the slide, containing the title and author information in white text.

Evaluating the Impact of Timing of Therapy on Tuberculosis Risk in HIV Patients

By: Scott Cleven, Margaux Douvier, and Katiely Muñoz

HIV

- As of 2017, roughly 36.9 million individuals around the world are infected with HIV that causes AIDS.
- According to WHO, 1.1 million people died from AIDS in 2016.
- At the beginning of the HIV/AIDS epidemic, most HIV infected individuals died within 10 years of infection.

ART Therapy

- HIV attacks the immune system's **CD4** cells causing those infected with HIV to be much more susceptible to disease(s).
- While HIV has no cure, **ART is recommended** to help control the severity of the virus.
- ART helps with...
 - Suppressing viruses and diseases
 - Rebuilding the immune system
 - Reducing HIV associated complications

HIV in Haiti

- About 150,000 people in Haiti have HIV/AIDS.
- Only 55% of those people received ART treatment.
- Haiti also has **limited resources** to help those with HIV.
 - In accordance with the WHO guideline, ART treatment doesn't begin until after CD4 counts fall below 200 cells/mm³.



SO YOU THINK 200 CELLS/MM³ IS A GOOD CUTOFF HUH?



WHO saying you should receive treatment after your CD4 cell count falls below 200 cells/mm³

Us:

CIPRA HT-001 Study

- This study tried to investigate whether the WHO guideline is sufficient or not.
- 773 subjects from Haiti had baseline CD4 counts between 200 and 350 cells/mm³.
- They were randomly assigned to two ART treatment groups:
 - Standard (delayed) group: Subjects initiated treatment according to the WHO guideline
 - Early group: Subjects received ART at enrollment of study

Tuberculosis

- The clinical end-point of this study is **incidence of tuberculosis** (TB).
- The symptoms used to identify TB in this study were fever, night sweats, weight loss, cough, dyspnea, hemoptysis, and lymphadenopathy.
- Final diagnosis were confirmed if *M. tuberculosis* culture was positive.
- **Population of interest:** Individuals in Haiti with HIV that received antiretroviral therapy (ART) during study and didn't have tuberculosis at baseline.

Delayed Vs. Early Analysis

We ran a **logistic regression model** to compare the incidence of tuberculosis between delayed and early groups.

$$\widehat{\text{logit}}(Y) = \widehat{\beta}_0 + \widehat{\beta}_1 * \text{Delay}$$

Y is 1 if patient has TB; 0 if not

Delay is 1 if patient is in delayed group; 0 if in early group.

	Parameter Estimate	Z-Value	Pr(> z)		Odds Ratio
Intercept	-2.457	-12.91	2e-16	***	
Delay	0.954	4.05	5.17e-5	***	2.597


With the estimated odds of 2.597, individuals are more susceptible to contracting tuberculosis in the delayed group.

Evaluate the Impact of Timing of ART Initiation

- Timing of ART depends on the guideline.
- Investigate whether timing of ART initiation is associated with TB incidence.
- We conducted the subgrouping analyses in the delayed group.

Design of Subgroups

- Based on the median cutoff we made two groups
 - More delayed group (greater than 1.33)
 - Less delayed group (less than or equal to 1.33)



Based on the WHO guidelines, the median year to ART is 1.33 years

Comparison of Subgroups

More Delayed Vs. Early

$$\widehat{\text{logit}}(Y) = \widehat{\beta}_0 + \widehat{\beta}_1 * \text{Moredelay}$$

	Parameter Estimate	Z-Value	Pr(> z)	Odds Ratio
Intercept	-2.456	-12.910	2e-16 ***	
MoreDelayed	1.042	3.860	0.0001 ***	2.833

Less Delayed Vs. Early

$$\widehat{\text{logit}}(Y) = \widehat{\beta}_0 + \widehat{\beta}_1 * \text{Lessdelay}$$

	Parameter Estimate	Z-Value	Pr(> z)	Odds Ratio
Intercept	-2.457	-12.910	2e-16***	
LessDelayed	0.861	3.090	0.002***	2.366

Both odds ratios are greater than 1.

$1 < \text{OR}(\text{Less Delayed}) < \text{OR}(\text{Delayed Vs. Early}) < \text{OR}(\text{More Delayed})$

$2.3660 < \mathbf{2.5971} < 2.8334$

Characterization of Patients between Less Delayed and More Delayed Group

$$\widehat{\text{logit}}(Y) = \widehat{\beta}_0 + \widehat{\beta}_1 * \text{Sex} + \widehat{\beta}_2 * \text{Age} + \widehat{\beta}_3 * \text{BMI} + \widehat{\beta}_4 * \text{Hemoglobin} + \widehat{\beta}_5 * \text{CD4} + \widehat{\beta}_6 * \text{PPD Test}$$

Y = 1 if subject is in More Delayed subgroup
Delayed subgroup

Y = 0 if patient is in Less
Delayed subgroup

The predictors are:

- Sex (1 if male, 0 if female)
- Age (years)
- BMI (kg/m²)
- Hemoglobin(g/dl)
- CD4 (cells/mm³)
- PPD Test (1 if patient received PPD test, 0 if not)

The Result of Analyses: Comparing More and Less Delayed

	Parameter Estimate	Z-Value	Pr(> z)
Intercept	-6.414	-4.347	0.00001 ***
Sex	0.225	0.837	0.4027
Age	0.003	0.223	0.8237
BMI	-0.033	-0.977	0.3285
Hemoglobin	0.312	3.739	0.0001 ***
CD4	0.012	3.724	0.0002 ***
PPD Test	-0.052	-0.214	0.8305

Conclusion

- Delayed therapy increases the odds of contracting tuberculosis
- Subgrouping into More and Less Delayed
- Higher CD4 and hemoglobin at baseline means more delayed treatment.
- Healthier individuals are at greater risk of contracting tuberculosis.
- Based on our analyses, we can conclude that WHO guideline can play a different role depending on the individual.



Thank You

- Ryan Cho
- All the Biostatistics faculty
- Our ISIB cohort
- The NHLBI
- ISIB Program sponsored by the National Heart Lung and Blood Institute (NHLBI), grant # HL147231